ArticleWorld journal of gastrointestinal oncology2025
Tumour chemotherapy sensitivity test may predict clinical outcomes in colorectal cancer patients receiving oxaliplatin and fluoropyrimidine-based regimens.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut microbiota-mediated chemotherapy resistance in colorectal cancer: mechanisms and precision interventions.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy is an essential treatment for colorectal cancer (CRC) patients after surgery, but many patients do not benefit from chemotherapy because tumour heterogeneity results in varied responses.
aimTo study the effectiveness of
methodsBetween January 2015 to December 2021, a total of 1549 CRC patients underwent surgery and
resultsTumour heterogeneity and resistance to multiple drugs were observed in 1549 patients. The sensitivity to 5-fluorouracil (5-FU) combined with L-OPH was tested among 1474 of these patients, yielding a sensitivity rate of 11.9%. ATP-TCA results were identified as an independent prognostic factor for DFS [
conclusionThe response of CRC patients to the combination regimen of 5-FU and L-OPH is heterogeneous. This study confirmed that the ATP-TCA is a valuable tool for predicting clinical outcomes, such as DFS, in patients with resectable CRC receiving chemotherapy. Although further validation with multicentre data is still necessary, these findings support that the ATP-TCA may function as a guiding tool for personalized chemotherapy administration, thereby optimizing treatment opportunities for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.